Profile of nimotuzumab in the treatment of high-grade glioma - Wikidata - awgldk - TriplyDB

Profile of nimotuzumab in the treatment of high-grade glioma

Profile of nimotuzumab in the treatment of high-grade glioma

http://www.wikidata.org/entity/Q35491503

about

Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas.Successful treatment with apatinib for refractory recurrent malignant gliomas: a case series.Radiotherapy Upregulates Programmed Death Ligand-1 through the Pathways Downstream of Epidermal Growth Factor Receptor in Glioma.Trends in Malignant Glioma Monoclonal Antibody Therapy.

P2860

Q36962460-FAEBE8AD-75AB-4213-AC2A-B6F05F188201 Q37653025-025E8851-11DD-4AAA-8EF0-76386CE9AB3C Q49359610-D813B423-CE0B-493E-BBAA-E441F6291D8F Q54942652-7FFE44F9-99DE-4B4C-95C6-016315879068

P2860

Profile of nimotuzumab in the treatment of high-grade glioma

http://www.wikidata.org/entity/Q35491503

description

2015 nî lūn-bûn

@nan

2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Profile of nimotuzumab in the treatment of high-grade glioma

@ast

Profile of nimotuzumab in the treatment of high-grade glioma

@en

type

label

Profile of nimotuzumab in the treatment of high-grade glioma

@ast

Profile of nimotuzumab in the treatment of high-grade glioma

@en

prefLabel

Profile of nimotuzumab in the treatment of high-grade glioma

@ast

Profile of nimotuzumab in the treatment of high-grade glioma

@en

P1433

Q35491503-4FAF75D1-CF92-4D17-B29C-BB1D9B598045

P1476

Q35491503-A2E8D0CB-90EE-4222-B48F-A8F83E991A9E

P2093

Q35491503-5E7BF28D-2E58-4A27-8A20-B9161506FD7A

Q35491503-84D8D280-53FC-4F5B-A467-D1A67AD33183

Q35491503-A0EBEBD5-AFEA-4465-A061-5F92E115835C

P2860

Q35491503-0BA0FDB2-1583-4886-B82E-C9F20E1FBC4D

Q35491503-17B6D00F-A156-48C9-A375-4F3C63D899EB

Q35491503-25740C47-606D-405F-B1A3-EF6C21A8B464

Q35491503-3AF55C1E-8C67-4625-9260-ABE8D67178BC

Q35491503-3B6F41AA-CA70-49E4-AB21-68236AA8F64F

Q35491503-40483CC9-776D-434B-9B44-ACC506E9D055

Q35491503-41CCBA9B-6BD4-48CC-AEFB-CC62BCA1FDCB

Q35491503-4A81F1F7-708A-44FD-8C6C-66BC9C237AF3

Q35491503-52821C7C-A5C7-4513-91AB-00DD77842234

Q35491503-5C6E2C74-0680-478E-A067-9086D2F4A04C

P304

Q35491503-CE724E47-ADB3-4DEF-BF83-6A71CE476149

P31

Q35491503-C1D2E95C-3509-41C4-9FFD-D8351B8C822F

P356

Q35491503-E67219B5-A791-4FB7-B4EB-697FA33740E5

P407

Q35491503-BBA07D5F-83AD-49FA-A908-415CFFF6D61B

P478

Q35491503-98E33ED9-4086-47BE-8671-67E738818C0B

P577

Q35491503-45739653-2A2B-4ADF-A82C-5C607BF50956

P698

Q35491503-79F6F28F-4BB0-4BEA-8EC9-587A92242F0F

P932

Q35491503-25D79662-0A72-4EA6-BB96-315BD65EE632

P356

P1433

OncoTargets and Therapy

P1476

Profile of nimotuzumab in the treatment of high-grade glioma

@en

P2093

Cheng-Cheng Guo

http://www.w3.org/2001/XMLSchema#string

Qun-Ying Yang

http://www.w3.org/2001/XMLSchema#string

Zhong-Ping Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

[Nimotuzumab in combination with chemotherapy for patients with malignant gliomas].

Nimotuzumab in combination with radiotherapy in high grade glioma patients: a single institution experience.

Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma.

Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial.

Nimotuzumab prolongs survival in patients with malignant gliomas: A phase I/II clinical study of concomitant radiochemotherapy with or without nimotuzumab

P304

819-825

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OTT.S60032

http://www.w3.org/2001/XMLSchema#string

P407

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2015-04-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25926743

http://www.w3.org/2001/XMLSchema#string

P932

4403697

http://www.w3.org/2001/XMLSchema#string